iRadimed Corporation (NASDAQ:IRMD) Stock Has Average Target Price of $120.00

iRadimed Corporation (NASDAQ:IRMD) has been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $120.00.

Several equities analysts have recently commented on IRMD shares. Needham & Company LLC initiated coverage on iRadimed in a research report on Tuesday, September 22nd. They issued a “hold” rating on the stock. Weiss Ratings raised shares of iRadimed from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, October 16th. Finally, Wall Street Zen cut shares of iRadimed from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th.

Key iRadimed News

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Record revenue and year-over-year growth: Third-quarter revenue reached $24.2 million, up 14% from the prior-year period and 18% sequentially. Revenue also exceeded the FactSet consensus estimate of $23.5 million. iRadimed Third Quarter 2026 Financial Results
• Positive Sentiment: Improved profitability: GAAP diluted EPS was $0.51, while non-GAAP diluted EPS was $0.55, up from $0.41 and $0.47, respectively, in the second quarter. Non-GAAP EPS matched analysts’ consensus estimate, while the company maintained a 26.7% net margin and 23.45% return on equity. IRadimed Q3 Earnings and Outlook
• Positive Sentiment: Potential production acceleration: Management expects fourth-quarter revenue of $25 million to $26.5 million and is targeting more than 50% sequential growth in output for its MRidium 3870 infusion pump, supporting a potential path toward a $100 million annual revenue run rate. iRadimed Q4 Revenue Outlook

iRadimed Price Performance

Shares of IRMD opened at $76.68 on Friday. The firm has a market capitalization of $980.74 million, a P/E ratio of 47.90 and a beta of 0.91. The business has a fifty day moving average of $85.66 and a 200 day moving average of $92.69. iRadimed has a one year low of $76.35 and a one year high of $107.90.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Friday, October 30th. The medical equipment provider reported $0.55 earnings per share for the quarter, hitting the consensus estimate of $0.55. The business had revenue of $24.20 million for the quarter, compared to the consensus estimate of $23.47 million. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. Analysts expect that iRadimed will post 1.98 EPS for the current fiscal year.

Insider Buying and Selling

In other iRadimed news, Director Monty K. Allen sold 1,419 shares of the stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $86.41, for a total transaction of $122,615.79. Following the completion of the transaction, the director owned 19,581 shares of the company’s stock, valued at $1,691,994.21. This represents a 6.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 34.60% of the stock is currently owned by insiders.

Institutional Trading of iRadimed

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. purchased a new position in shares of iRadimed during the second quarter valued at approximately $92,485,000. Ranger Investment Management L.P. purchased a new stake in shares of iRadimed in the second quarter worth approximately $9,398,000. Bank of New York Mellon Corp purchased a new stake in shares of iRadimed in the second quarter worth approximately $7,252,000. Rice Hall James & Associates LLC bought a new stake in shares of iRadimed during the 2nd quarter worth approximately $2,909,000. Finally, Bridge City Capital LLC boosted its stake in shares of iRadimed by 36.5% during the third quarter. Bridge City Capital LLC now owns 96,975 shares of the medical equipment provider’s stock valued at $8,361,000 after purchasing an additional 25,932 shares during the period. 92.34% of the stock is owned by hedge funds and other institutional investors.

About iRadimed

iRadimed Corporation (NASDAQ: IRMD) develops, manufactures and sells medical devices designed for use during magnetic resonance imaging (MRI) procedures. The company focuses on solutions that allow clinicians to deliver intravenous medications and monitor patients safely while they are in or near an MRI scanner.

Its principal products include the MRidium MRI-compatible infusion pump systems, which are designed to administer intravenous fluids and medications without interfering with MRI operations.